Caveolin-1 scaffolding domain peptide regulates glucose metabolism in lung fibrosis

Venkadesaperumal Gopu, Liang Fan, Rashmi S. Shetty, M.R. Nagaraja, and Sreerama Shetty
Texas Lung Injury Institute, Department of Medicine, University of Texas Health Science Center at Tyler (UTHCT), Tyler, Texas, USA.

Increased metabolism distinguishes myofibroblasts or fibrotic lung fibroblasts (fLfs) from the normal lung fibroblasts (nLfs). The mechanism of metabolic activation in fLfs has not been fully elucidated. Furthermore, the antifibrogenic effects of caveolin-1 scaffolding domain peptide CSP/CSP7 involving metabolic reprogramming in fLfs are unclear. We therefore analyzed lactate and succinate levels, as well as the expression of glycolytic enzymes and hypoxia inducible factor-1α (HIF-1α). Lactate and succinate levels, as well as the basal expression of glycolytic enzymes and HIF-1α, were increased in fLfs. These changes were reversed following restoration of p53 or its transcriptional target microRNA-34a (miR-34a) expression in fLfs. Conversely, inhibition of basal p53 or miR-34a increased glucose metabolism, glycolytic enzymes, and HIF-1α in nLfs. Treatment of fLfs or mice having bleomycin- or Ad-TGF-β1-induced lung fibrosis with CSP/CSP7 reduced the expression of glycolytic enzymes and HIF-1α. Furthermore, inhibition of p53 or miR-34a abrogated CSP/CSP7-mediated restoration of glycolytic flux in fLfs in vitro and in mice with pulmonary fibrosis and lacking p53 or miR-34a expression in fibroblasts in vivo. Our data indicate that dysregulation of glucose metabolism in fLfs is causally linked to loss of basal expression of p53 and miR-34a. Treatment with CSP/CSP7 constrains aberrant glucose metabolism through restoration of p53 and miR-34a.

Introduction
Glucose metabolism begins with its conversion to pyruvate through sequences of biochemical reactions termed glycolysis. During aerobic respiration, pyruvate is transported into mitochondria to be converted into CO2 and the acetyl portion of acetyl coenzyme A. This process produces nicotinamide adenine dinucleotide (NADH), which later goes through oxidative phosphorylation (1–3). However, under anaerobic conditions, pyruvate is converted to lactate in the cytoplasm (4, 5). Increased conversion of glucose to lactate can occur under both aerobic and anaerobic conditions. One of the distinctions of cancer cells is that they metabolize glucose by glycolysis, whereas noncancerous cells metabolize glucose by oxidative phosphorylation (1, 6). The major shift to aerobic glycolysis with lactate production, with increased uptake of glucose, is likely used by proliferating carcinoma cells to promote the efficient conversion of glucose into the macromolecules required for increased cellular mass (7, 8). This metabolic change, termed the Warburg effect, is a key event during tumor progression (9, 10). Increased metabolic activation and production of lactate has been reported in tumors surrounding stromal fibroblasts, which nourish tumor cells. Increased aerobic glycolysis in stromal cells results in increased production and secretion of lactate. The lactate is then transferred to adjacent cancer cells and converted to pyruvate, which functions as a substrate for mitochondrial oxidative phosphorylation (1, 6). A relative deficiency of caveolin-1 (CAV1) in tumor-associated fibroblasts has been postulated to underlie the reverse Warburg effect, in which cancer cell oxidants down-regulate CAV1 in stromal fibroblasts that are tumorigenic in breast cancers (11, 12).

Interstitial lung diseases (ILDs) — including one of its most common types, idiopathic pulmonary fibrosis (IPF) — are progressive and debilitating lung diseases. These diseases are fatal, with a postdiagnosis median survival of less than 3 years (13, 14). Activated myofibroblasts are important contributors for normal wound repair processes that eventually undergo apoptosis. However, activated myofibroblasts or fibrotic lung fibroblasts (fLfs) in IPF lungs resist apoptosis and exhibit excessive proliferation and migration.
This leads to a progressive accumulation of these cells. Since diagnosis of IPF is often in the advanced stages of disease development, there is a strong consensus to target fLfs to effectively mitigate IPF and other progressive fibrotic disorders. Multiple recent reports have indicated higher glycolytic activity in fibrotic areas and fLfs isolated from IPF lungs. These studies have implicated a persistent state of activation of fLfs to upregulated key glycolytic enzymes (15, 16). Metabolic reprogramming of fLfs has been implicated in the pathogenesis of IPF. Glucose transporter proteins, particularly GLUT1, play an important role in metabolic activation of cells. GLUT1 expression is regulated by changes in metabolic state and oxidative stress, which involve signaling molecules such as cyclic adenosine monophosphate (cAMP), p53, PI3-kinase, and AKT (17–20). Inhibition of GLUT1 reduced α-SMA expression in lung fibroblasts (21), indicating a direct link between glycolytic activation and profibrogenic transformation of fLfs.

In the present study, we found that key enzymes that catalyze aerobic glycolysis are induced in human fLfs (hfLfs) isolated from IPF lungs or WT mouse fLfs (mfLfs) isolated from lungs of mice with established pulmonary fibrosis. We (22) and others (23, 24) have reported that CAV1 expression is markedly reduced in fLfs. Restoration of CAV1 expression or treatment with CAV1 scaffolding domain peptide (CSP) — or its 7-amino acid deletion fragment CSP7 — inhibits expression of profibrotic marker proteins in fLfs (22, 25). We further found that treatment of fLfs with CSP or CSP7 inhibited the increase in glycolysis in fLfs, which was associated with the antifibrogenic effects of these peptides. The process involves restoration of baseline p53 and its downstream transcriptional target, microRNA-34a (miR-34a) expression, which are otherwise reduced in hfLfs or mfLfs. Our study has established that CSP7-mediated restoration of baseline p53 and miR-34a mitigates fibrotic phenotypes by restraining augmented glycolysis in fLfs.

Results

Dysregulated glucose metabolism in fLfs. To determine the dysregulated glucose metabolism during mesenchymal cell dedifferentiation, normal lung fibroblasts (nLfs) — isolated from human donors without ILDs or mice without experimentally induced lung injury — and fLfs were tested for cellular lactate and succinate levels. We found that both lactate (Figure 1A) and succinate (Figure 1B) levels were significantly increased in hfLfs and mfLfs when compared with their expression in corresponding nLfs. To confirm that glycolytic reprogramming does occur in vivo, we measured lactate levels in lung tissues of mice with bleomycin-induced (BLM-induced) established pulmonary fibrosis. As shown in the Figure 1C, lactate levels were markedly increased in the fibrotic lung tissues of mice with BLM-induced lung injury, compared with lactate levels in normal lung tissues of mice without BLM lung injury. We assessed the relative expression of key enzymes that control glycolytic flux rate in murine and human nLfs and fLfs. We found that glycolytic enzymes such as hexokinase-2 (HK2), pyruvate kinase (PKM), phosphofructokinase (PFK), and phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) levels were markedly upregulated in mfLfs and hfLfs (Figure 1D). These changes were associated with a parallel increase in hypoxia inducible factor-1a (HIF-1α), a key transcriptional factor that drives anaerobic glycolysis. Consistent with protein expression, quantitative PCR (qPCR) analyses using primers listed in Table 1 revealed a significant increase in the expression of their mRNAs in hfLfs (Figure 1E) and mfLfs (Figure 1F). These results clearly suggest altered glycolysis in differentiated fLfs.

p53 regulates enzymes involved in glucose metabolism. To examine the role of p53 regulation of glucose metabolism, primary fLfs isolated from the lungs of IPF patients or mice with existing pulmonary fibrosis were transduced with adenoviral vector–expressing p53 (Ad-p53) or adenoviral empty vector (Ad-Ev). Overexpression of p53 in hfLfs from IPF tissue explants reduced the expression of HK2, PKM, PFKP, PFKFB3, and HIF-1α, while naive fLfs or fLfs exposed to Ad-Ev still displayed elevated baseline levels of glycolytic enzymes (Figure 2A). Consistent with these findings, corresponding mRNA levels of these enzymes and HIF1A were decreased following forced expression of p53 in fLfs (Figure 2B). To confirm whether the blockade of p53 expression contributes to augmented glycolysis, we treated nLfs with lentiviral vector–expressing (Lv-expressing) p53 shRNA. Control nLfs were left untreated or exposed to Lv-expressing control shRNA (Ctrl shRNA). Inhibition of p53 expression in nLfs using specific shRNA augmented the expression of HK2, PKM, PFKP, PFKFB3, and HIF-1α, while nLfs exposed to Lv Ctrl shRNA failed to increase in the basal expression of these enzymes (Figure 2C). This was further confirmed at the mRNA levels (Figure 2D), demonstrating a link between loss of baseline p53 to glycolytic reprogramming in fLfs.

miR-34a regulates glucose metabolism. Activation of p53 induces various noncoding miRNAs, particularly miR-34a. Thus, to elucidate the possible role of miR-34a in regulating glucose metabolism, hfLfs were transduced...
with Lv-expressing precursor miR-34a (Lv–Pre–miR-34a) or Lv-Ev. HK2, PFKP, PKM, PFKFB3, and HIF1A transcriptions were repressed when hFLFs were infected with the Lv-expressing miR-34a, which led to a decrease in protein levels (Figure 3A). hFLFs infected with Lv-Ev showed no significant difference in either mRNA (Figure 3B) and protein level when compared with the naive cells. To further investigate whether reduced expression of these enzymes is directly related to restoration of miR-34a, we treated human nFLFs with Lv-expressing miR-34a antisense (Lv–miR-34a–As). We found that inhibition of miR-34a augmented the levels of HK2, PFKP, PKM, PFKFB3, and HIF-1α protein (Figure 3C) and their mRNAs (Figure 3D). This indicates that miR-34a directly regulates the expression of enzymes involved in glucose metabolism.
CSP and CSP7 regulate glycolysis in fLfs. We recently demonstrated that CSP or its deletion fragment CSP7 exerts antifibrotic responses through restoration of baseline p53 and PAI-1 expression in fLfs (22, 25). To test whether this process involves changes in glycolytic flux, hfLfs were treated with CSP or CSP7 or control peptide of scrambled sequence (CP) as we described earlier (22). As shown in the Figure 4A, treatment of hfLfs with either CSP or CSP7 has caused a marked reduction in the expression of HK2, PKM, PFKP, PFKFB3, and HIF-1α. These changes were associated with parallel increase in basal p53 expression in hfLfs. Naive hfLfs and hfLfs treated with CP still showed elevated levels of glycolytic enzymes and low baseline p53. Consistent with protein expression, we also found significant reduction in the expression of HK2, PKM, PFKP, PFKFB3, and HIF1A mRNA in hfLfs treated with CSP or CSP7, while those exposed to CP failed to respond to the treatment (Figure 4B). These changes were further reflected with significant reduction in otherwise elevated cellular lactate levels in hfLfs treated with CSP or CSP7 when compared with those exposed to CP (Figure 4C).

CSP or CSP7 attenuates elevated glucose metabolism in mice with single-dose (1×) BLM-induced pulmonary fibrosis. We recently reported that both CSP or CSP7 treatment resolves existing pulmonary fibrosis in WT mice (22, 25). To test whether these antifibrogenic peptides can restore dysregulated glucose metabolism in mice with lung fibrosis, we started CSP or CSP7 treatment by daily i.p. injection 2 weeks after intranasal instillation of BLM as shown in Figure 5A. Treatment of mice having BLM-induced established pulmonary fibrosis with either CSP or CSP7 resulted in a significant reduction in total lung lactate levels, suggesting reversal of augmented glycolysis observed in mice with BLM-induced pulmonary fibrosis (Figure 5B). Total lung homogenates of WT mice exposed to BLM showed elevated expression of glycolytic markers. Mice treated with CSP or CSP7 exhibited a marked reduction in the expression of screened glycolytic enzymes, along with restoration of basal p53 expression (Figure 5C) and attenuation of BLM-induced lung fibrosis (22, 25). Consistent with protein expression, we also found that the expression of Hk2, Pkm, Pfkp, Pfkb3, and Hif1a mRNA in hfLfs treated with CSP or CSP7, while those exposed to CP failed to respond to the treatment (Figure 4B). These changes were further reflected with significant reduction in otherwise elevated cellular lactate levels in hfLfs treated with CSP or CSP7 when compared with those exposed to CP (Figure 4C).

Table 1. List of primer sequences used for gene expression analysis by qPCR.

| Target | Oligo sequence (5′-3′) |
|--------|-----------------------|
| HK2    | FWD: GAGGAACCAATTTTCGTGCCTGCT RV: CCTTTGATCCTCCATGTACCTCAAGA |
| PKM    | FWD: TCGAGAAGCTCAGCGGTCCG TGCRT RV: CCACGGCAACCACGGCCGGA |
| PFKP   | FWD: TCTGGTCCAGTGGTATCTT RV: GCCATCCTACACTGTCG |
| PFKFB3 | FWD: ATGCCGTTGGAACTGACCCA RV: GCGTTCTATGCAACTGACAC |
| HIF1A  | FWD: GTCGGACAGGCTACAAACAGCAGTATG RV: CTTTGGTGAATAGCTGAGTCATTTTCA |
| ACTB   | FWD: CTTTGGTGAATAGCTGAGTCATTTTCA |

insight.jci.org   https://doi.org/10.1172/jci.insight.137969
was markedly reduced in mice exposed to CSP or CSP7. Consistent with the H&E staining pattern, IHC analysis confirmed reduced staining for PKM antigen in lung sections of mice following peptide treatment (Figure 5E). However, those exposed to CP still showed increased PKM antigen levels.

**Inhibition of augmented glucose metabolism in mice with TGF-β1–induced lung fibrosis by CSP or CSP7 in vivo.** To further test the effect of CSP or CSP7 on glucose metabolism, mice with adenoviral vector–expressing constitutively active TGF-β1–induced (Ad–TGF-β1–induced) established pulmonary fibrosis were daily exposed to CSP or CSP7 by i.p. injection for 2 weeks starting 14 days after Ad–TGF-β1 transduction (Figure 6A). As shown in Figure 6B, treatment of mice having existing lung fibrosis with either CSP or CSP7 significantly reduced total lactate levels in lung tissues. However, this did not occur in mice with Ad–TGF-β1–induced lung fibrosis left untreated or exposed to CP. The changes in total lactate levels were associated with marked reduction in Ad–TGF-β1–induced pulmonary collagen deposition in mice exposed to CSP or CSP7, compared with that of CP-treated mice (25), indicating a causal link between dysregulated glycolysis and profibrogenic remodeling. Immunoblotting of total lung homogenates from WT mice exposed to Ad–TGF-β1 showed a striking increase in the expression of HK2, PKM, PFKP, PFKFB3, and HIF-1α. These changes were remarkably reduced in WT mice harboring lung fibrosis and treated with CSP or CSP7, illustrating reversal of glycolytic reprogramming and dedifferentiation of fLfs (Figure 6C). In agreement with protein expression, qPCR analysis of whole lung total RNA of Ad–TGF-β1–treated mice showed a significant increase in the expression of HK2, Pkm, Pfkp, Pfkfb3, and Hif1a transcripts compared with the corresponding levels in untreated or Ad-Ev–treated control mice. However, these changes were significantly suppressed to baseline levels in WT mice exposed to Ad–TGF-β1 and later treated with CSP or CSP7, while their expression levels remained elevated in mice treated with CP (Figure 6D). H&E staining.
of lung sections indicated Ad–TGF-β1–induced pulmonary fibrosis, which was markedly reduced in those treated with CSP or CSP7 (Figure 6E). IHC analysis further confirmed the inhibition of the otherwise BLM-induced increase in PKM antigen staining in the lung tissues of mice after treatment with either CSP or CSP7. However, elevated staining for PKM was observed in lung sections of WT mice exposed to Ad–TGF-β1 and treated with CP.

Mitigation of multihit (8×) BLM-induced aberration in glycolysis by CSP or CSP7 in vivo. To further test the glycolytic regulatory effect of CSP or CSP7, we performed a similar experiment with the 8× BLM–induced established pulmonary fibrosis model. CSP or CSP7 was given daily by i.p. injection for 2 weeks after the eighth dosage of BLM (Figure 7A). As shown in Figure 7B, CSP or CSP7 reduced BLM-induced total lung lactate levels, while those exposed to CP remained unchanged. These changes were associated with a significant reduction in BLM-induced whole lung collagen content in WT mice exposed to CSP or CSP7 and not in those treated with CP (22, 25), indicating resolution of existing pulmonary fibrosis. Further analysis of total lung homogenates of WT mice exposed to 8× BLM showed increased expression of HK2, PKM, PFKFB3, and HIF-1α, which was consistent with changes observed in mice treated with single dose BLM and Ad–TGF-β1. Further, reversal of 8× BLM–induced changes was observed in mice treated with CSP or CSP7, restored near normal baseline expression of the glycolytic enzymes (Figure 7C), along with attenuation of BLM-induced lung fibrosis (22, 25). Consistent with protein expression, we also found that Hk2, Pkm, Pfkp, and Pfkfb3 mRNA were similarly elevated in the lungs of these mice. This was significantly reversed in mice exposed to BLM and treated with CSP or CSP7, while those treated with CP still showed elevated mRNA expression (Figure 7D). H&E staining of lung sections indicated BLM-induced pulmonary fibrosis, which was markedly reduced in those treated with either CSP or CSP7 (Figure 7E).
IHC analysis further confirmed the inhibition of the otherwise BLM-induced increase in PKM antigen staining in the lung tissues of mice after CSP or CSP7 treatment. However, elevated staining for PKM antigen was apparent in lung sections of mice treated with CP after causing BLM-induced pulmonary fibrosis.

Inhibition of p53 abrogates CSP- and CSP7-mediated restoration of glycolytic flux rate. To confirm that the restoration of p53 expression is required for the reversal of dysregulated glycolysis by CSP or CSP7 in hfLfs, we transduced fLfs with p53 shRNA and later treated these fLf lines with either CSP7 or CP. The responses were compared with naive hfLfs treated with CSP7 or CP, or hfLfs transduced with Ctrl shRNA and treated with CSP7 or CP. As showed in Figure 8A, CSP7 treatment reduced expression of glycolytic markers in naive hfLfs or fLfs transduced with Ctrl shRNA, indicating its beneficial effects in fLfs. These changes were associated with elevation of basal p53 levels by CSP7 treatment. Interestingly, these effects were not found in fLfs treated with p53 shRNA. This was further confirmed at the HK2, PFKP, PKM, PFKFB3, and HIF1A mRNA levels (Figure 8B). These findings were consistent with lack of suppression of profibrogenic markers, proliferation, migration, and invasion by CSP or CSP7 in fLfs treated with p53 shRNA (22).

To further confirm the involvement of p53 in regulation of glycolysis in fLfs in vivo, tamoxifen inducible conditional KO mice lacking p53 expression in fibroblasts (p53cKO mice) were exposed to BLM, and 14 days later, these mice were exposed to vehicle, CSP, or CSP7 under same condition were used as controls. Pulmonary fibrosis induced with BLM caused dysregulation in glycolysis in both p53fl/fl (Figure 8, C and D) and p53cKO (Figure 8, E and F) mice, as indicated by the increased expression of HK2, PKM, PFKP, PFKFB3, and HIF-1α protein in whole lung homogenates. Interestingly, neither CSP nor its deletion fragment CSP7 reduced BLM-induced increases in the expression of glycolytic enzymes in p53cKO mice. However, p53fl/fl mice exposed to either CSP or CSP7 showed remarkable suppression of glycolytic pathway markers. These changes were associated with concurrent restoration of baseline p53 level, which is otherwise suppressed due to BLM-induced pulmonary fibrosis. Further analysis of total lung RNA for glycolytic marker mRNA confirmed that both CSP and CSP7 were effective against altered metabolism in p53cKO mice. This is in conformity with the resistance of p53cKO and having pulmonary fibrosis to CSP7 or CSP7 treatment (22). The inability of CSP or CSP7 to suppress augmented glycolysis in BLM treated p53cKO mice validates that CSP7-mediated restoration of baseline expression of p53 is required for resolution of existing lung fibrosis through the regulation of glucose metabolism.

Inhibition of miR-34a abrogates regulatory effects of CSP7 in vitro and in vivo. To confirm the involvement of miR-34a in the regulation of altered glucose metabolism by CSP7, we transduced hfLfs with Lv–miR-34a–As and later treated these cells with CSP7 or CP. The responses were compared with naive hfLfs or hfLfs transduced with Lv-Ev and treated with CSP7 or CP. Treatment with CSP7 caused marked reduction
in the expression of glycolytic markers, indicating its regulatory effect in naive fLfs. These changes were not found in fLfs transduced with Lv–miR-34a–As (Figure 9A). This was further reflected at the levels of HK2, PFKP, PKM, PFKFB3, and HIF1A mRNA expression (Figure 9B).

miR34a fl/fl ColCre mice, generated by cross-breeding miR34a fl/fl mice with Col1 Cre mice, were i.p. injected with tamoxifen to suppress expression of miR-34a in fibroblasts through induction of Cre-recombinase. Tamoxifen inducible miR34a cKO mice, lacking miR-34a expression in fibroblasts, were exposed to BLM, and 14 days later, these mice were exposed to vehicle, CSP, CSP7, or CP. miR34a fl/fl mice under the same treatment conditions were used as controls. miR34a fl/fl and miR34a cKO mice showed increased expression of HK2, PFKP, PKM, PFKFB3, and HIF-1α in whole lung homogenates 21 days after BLM lung injury.

Figure 5. CSP7 attenuates augmented glycolysis in WT mice with BLM-induced pulmonary fibrosis. (A) Schematic illustration of the experimental design. WT mice were exposed once to BLM (8 U/kg in 50 μL saline) through intranasal instillation to cause established pulmonary fibrosis. Two weeks after BLM exposure, mice were treated with 1.5 mg/kg of CSP, CSP7, or CP via i.p. injection daily for 7 consecutive days. All mice were euthanized 21 days after BLM exposure. (B) The lungs were harvested, and lung homogenates were tested for total lactate. (C) Total lung homogenates were evaluated for the changes in the expression of HK2, PFKP, PFKFB3, and HIF-1α proteins by Western blotting. The experiments were repeated 2 times. (D) Total mouse lung RNA was analyzed for Hk2, Pkm, Pfkp, Pfkfb3, and Hif1a mRNA by qPCR. Data pooled from 2 independent experiments (n = 6 per group) are represented as mean ± SD. **P < 0.01, ***P < 0.001, ****P < 0.0001 were obtained by 1-way ANOVA followed by Tukey’s post hoc test. (E) The lung sections were subjected to histological analysis, and representative images of H&E and IHC staining for PKM are shown. Scale bars: 200 μm.
As expected, miR34a<sup>−/−</sup> mice responded to peptide treatment (Figure 9, C and D), whereas — in miR34a<sup>−/−</sup> mice — CSP7 treatment did not reduce BLM-induced augmented glycolytic enzymes expression (Figure 9, E and F). This indicates that CSP7-mediated restoration of miR-34a downregulates the augmented glucose metabolism in fLfs. The inability of CSP7 to resolve augmented glycolysis in BLM-treated p53<sup>−/−</sup> or miR34a<sup>−/−</sup> mice establishes the importance of baseline p53 and miR-34a feedback induction in regulating fLfs glucose metabolism.

**Discussion**

Dysregulated metabolic changes have been involved in the pathogenesis of many diseases, including IPF. Altered glucose metabolism is one of the major distinguishing phenotypes between normal and cancer cells (4, 5, 15). The essential role of glycolytic enzymes like HK2 and PFKFB3 in maintaining the high glycolytic tumor phenotypes has been reported in recent years. Studies suggest that activation of HIF-1α stimulates the expression of
various glycolytic enzymes, which drives aerobic glycolysis for energy production (26). The mechanism contributing to glycolytic reprogramming in fibrotic lungs is not well established, and the metabolism-based therapeutics for treating fibrotic lung disorders are lacking. In the current study, we have shown that glycolysis is increased in fLfs isolated from the fibrotic lung explants derived from patients with IPF, or from multiple murine models of existing pulmonary fibrosis. We further demonstrated that the process involves loss of baseline p53 expression and its inducible downstream target, miR-34a, in fLfs of IPF lungs and mice with established lung fibrosis.

Aberrant glycolysis in fibrotic lungs was measured by the production of lactate and succinate—the end products of glycolysis and the TCA cycle intermediate, respectively. These were found to be...
elevated in fLfs compared with their basal levels of expression found in nLfs. This was further confirmed by an approximate 2-fold increase in lactate content in fibrotic lungs of mice in vivo. Screening for the expression of key rate-limiting enzymes suggested upregulation of HK2, PKM, PFKP, PFKFB3, and HIF-1α proteins. The experiments were repeated twice. (A) Total RNA isolated from n = 4 hnLfs, and hLfLfs treated as in A, were quantified by qPCR for above mentioned mRNA. p53ΔflΔ and tamoxifen inducible p53cKO mice (n = 6 per group) were exposed to saline or BLM. Two weeks after BLM injury, mice were treated with or without CSP, CSP7, or CP by i.p. injection daily for 7 consecutive days. (C and E) At the end of the treatment, mice were euthanized, and the lung homogenates from p53fl/fl (C) and p53cKO (E) mice were immunoblotted for the differential expression of marker enzymes involved in glycolysis. The experiments were repeated 2 times. (D and F) Total lung RNA from p53ΔflΔ (D) and p53cKO (F) mice were analyzed for Hk2, Pkm, Pfkp, Pfkfb3, and Hif1α mRNA by qPCR. Data pooled from 2 independent experiments are represented as mean ± SD and analyzed by 1-way ANOVA followed by Tukey’s post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 8. Inhibition of p53 abrogates the ability CSP or CSP7 to restore glycolysis in lungs. hLfLfs transduced with or without Lv-p53-shRNA or Ctrl shRNA were treated with PBS, CSP, or CP for 48 hours. Naïve hnLfs and hLfLfs were used as controls. (A) Cell lysates were immunoblotted for the differential expression of p53, HK2, PKM, PFKP, PFKFB3, and HIF-1α proteins. The experiments were repeated twice. (B) Total RNA isolated from n = 4 hnLfs, and hLfLfs treated as in A, were quantified by qPCR for above mentioned mRNA. p53ΔflΔ and tamoxifen inducible p53cKO mice (n = 6 per group) were exposed to saline or BLM. Two weeks after BLM injury, mice were treated with or without CSP, CSP7, or CP by i.p. injection daily for 7 consecutive days. (C and E) At the end of the treatment, mice were euthanized, and the lung homogenates from p53fl/fl (C) and p53cKO (E) mice were immunoblotted for the differential expression of marker enzymes involved in glycolysis. The experiments were repeated 2 times. (D and F) Total lung RNA from p53ΔflΔ (D) and p53cKO (F) mice were analyzed for Hk2, Pkm, Pfkp, Pfkfb3, and Hif1α mRNA by qPCR. Data pooled from 2 independent experiments are represented as mean ± SD and analyzed by 1-way ANOVA followed by Tukey’s post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001.
senescence in lung fibroblasts. We therefore examined whether expression of p53 and/or miR-34a regulates the suppression of glycolysis in fLfs and found that inhibition of either p53 or miR-34a in nLfs contributed to glycolytic upregulation. On the contrary, p53 and/or miR-34a overexpression in fLfs reduced the expression of glycolytic marker enzymes, suggesting glycolytic suppression. Like most cancer cells, fLfs rely on glycolysis, which ultimately produces lactate and 2 adenosine triphosphate (ATP) molecules from a single molecule of glucose. Glycolysis is less energy efficient than oxidative phosphorylation, which generates 36 ATPs per 1 glucose molecule. However, glycolysis can generate ATP faster than mitochondrial oxidative phosphorylation (31). In addition, glycolysis may provide intermediaries that are necessary for biosynthesis of amino acids, lipids, nucleotides, and lactate to maintain redox balance. Thus, glycolytic upregulation could confer survival benefits to fLfs, as seen in cancer cells (32). The importance of glycolysis in the pathogenesis of progressive fibrosis is further supported by the recent reports demonstrating pharmacological intervention that targets cellular metabolism, such as metformin or other activators of AMP-activated protein kinase (AMPK) mitigate

Figure 9. miR-34a inhibition revokes regulatory effect of CSP7. hLfs transduced with Lv–miR-34a–As or Lv–Ev were treated with PBS, CSP7, or CP for 48 hours. Naive hLfs and hLfs were used as controls. (A) Cell lysates were immunoblotted for the differential expression of HK2, PFKP, PKM, PFKFB3, and HIF-Fa. The experiments were repeated 2 times. (B) mRNA expression levels were quantified by qPCR (n = 4). miR34afl/fl and tamoxifen inducible miR34acKO mice (n = 6 per group) were exposed to saline or BLM. Two weeks after BLM injury, mice were i.p. injected with or without CSP7 or CP daily for 7 consecutive days. At the end of the treatment, mice were euthanized and the lung homogenate of miR34afl/fl (C) and miR34acKO (E) mice were immunoblotted for the differential expression of glycolytic markers. The experiments were repeated twice. (D and F) mRNA expression levels of mentioned genes from miR34afl/fl (D) and miR34acKO (F) mice were quantified by qPCR. Data pooled from 2 independent experiments are represented as mean ± SD and analyzed by 1-way ANOVA followed by Tukey’s post hoc test. ***P < 0.001.
pulmonary fibrosis through deactivation of myofibroblasts (15, 21, 33, 34). Furthermore, AMPK acts as an upstream activator of p53 and p53 transactivates Sestrin1 and Sestrin2, resulting AMP phosphorylation, which inhibits mTOR activity (35).

A principal component of caveoleae, CAV1, interacts with signaling proteins via CAV1 scaffolding domain (36). CAV1 has been reported in the regulation of numerous signaling pathways and biological processes. CAV1 expression is reduced in fLfs in fibrotic lung disease (24). Multiple mechanisms may be involved in p53 regulation. As a binding protein for MDM2, CAV1 stabilizes p53 via sequestering MDM2 away from p53. CAV1 activates p53 via inhibiting SIRT1 (37), and elevated basal expression of SIRT1 has been observed in fLfs (38), probably due to loss of baseline p53 and miR-34a feedback induction in these cells. Furthermore, loss of CAV1 in fLfs results in low membrane-associated phosphatase and tensin homolog (PTEN) expression leading to aberrant activation the PI3K/AKT signaling pathway (39). These changes could further enhance MDM2-mediated ubiquitination and degradation of p53 protein (40). We recently reported that expression of both CAV1 and p53 protein are markedly reduced in fLfs, and forced expression of CAV1 or CSP/CSP7 restored basal p53 and reduced profibrogenic proteins in fLfs (22, 25). Interestingly, CSP also inhibits BLM- or silica-induced lung injury and prevents development of pulmonary fibrosis by blocking otherwise increased p53 and miR-34a by competing with increased CAV1 expression in injured alveolar epithelial cells (41–43). In this study, we found that CSP or CSP7 attenuated the augmented glycolysis by inducing the expression of p53 and miR-34a, which are otherwise reduced in fLfs isolated from fibrotic lungs of patients with IPF or mice with BLM-induced established pulmonary fibrosis. This is consistent with resolution of existing lung fibrosis by CSP and its deletion fragment, CSP7, delivered systemically by i.p. injection, by liquid nebulization, or by inhalation of micronized dry powder via airways in 3 different preclinical mouse models (25). A comprehensive biochemical, histological, and protein expression study further revealed that CSP or CSP7 inhibited the augmented glycolysis, indicated by relatively lower levels of total lactate content in the fibrotic lung tissues.

To support our observation that CSP or CSP7 regulates glucose metabolism by controlling p53 and miR-34a expression through feedback induction in fLfs, we performed a similar set of experiments with tamoxifen inducible p53<sup>−/−</sup> or miR34a<sup>−/−</sup> mice lacking p53 or miR-34a expression in fibroblasts. Because CSP or CSP7 failed to resolve existing lung fibrosis in p53<sup>−/−</sup> (22) or miR34a<sup>−/−</sup> (data not shown) mice, we tested these mice for changes in glycolysis. As we expected, CSP and CSP7 failed to suppress the expression of glycolytic enzymes in fibroblast-specific p53<sup>−/−</sup> or miR34a<sup>−/−</sup> mice, unlike WT or respective floxed mice. These observations support the contention that CSP or CSP7 regulates glucose metabolism by restoring baseline expression of p53 and miR-34a through feedback induction, and the expression of p53 and miR-34a is otherwise lost in fLfs. Elevated glycolysis could contribute to profibrogenic phenotypes often exhibited by fLfs as excessive proliferation and resistance to apoptosis. Increased secretion of intermediaries of the glycolytic pathway, such as lactate in alveolar epithelial cell dysplasia, are most frequently observed in type II alveolar epithelial cells surrounding fibrotic foci in IPF lungs (44).

HIF-1α is a master transcriptional regulator of cellular and developmental response to hypoxia. HIF-1α stimulates multiple glycolytic gene expression (45, 46). It has been shown that p53 and miR-34a activities are modulated by the inhibition of its translation by the HIF-1α–induced RNA binding proteins (47). It is known that HIF-1α and p53 display opposing effects on glycolysis and mitochondrial respiration. HIF-1α stimulates glycolysis by inducing the expression of the majority of glycolytic enzymes, as well as glucose and lactate transporters, whereas p53 represses glycolysis, which is consistent with our findings. HIF-1α has been shown to regulate the expression of glycolytic enzymes and key transcriptional factors that drive glycolysis under hypoxic conditions (45, 48). It is also well recognized that HIF-1α plays an important role in tissue fibrosis (49–51). The mutual influence of p53 and HIF-1α is highly contradictory. However, there is ample evidence to support the contention that HIF-1α–mediated degradation decreases p53 levels (52, 53). Elevated levels of HIF-1α downregulates homeodomain-interacting protein kinase-2 (HIPK2), a tumor suppressor that impair p53 activity (54). It is also reported that, under hypoxic condition, MDM2 is upregulated at the mRNA level (53, 55), which may lead to increased ubiquitination of p53. We have also reported that CSP/CSP7 directly binds to MDM2 in the absence of CAV1 and inhibits MDM2-mediated ubiquitination of p53 (22). miR-34a may regulate HIF-1α via inhibiting SIRT1 translation (28, 56). HIF-1α can also inhibit expression of miR-34a as reported in isogenic colorectal cancer cells (57). Inhibition of HIF-1α may contribute to reduced PFKFB3, which may have occurred because of inhibition of hypoxic conditions due to CSP7 intervention. Increased succinate and HIF-1α in fibrotic lung tissues suggests that CSP7-mediated suppression of HIF-1α may be
linked to inhibition of the succinate activity. However, a recent report suggests that destabilization of HIF-1α has no effect on TGF-β1–induced PFKFB3 expression in lung fibroblasts (15). In addition, CSP7–mediated inhibition of α-SMA in fLfs (22, 25) may be associated with fLfs dedifferentiation due to inhibition of HIF-1α, as the latter binds to the α-SMA promoter to induce its transcription. HIF-1α also induces transcription of glycolytic enzymes such as HK (58) and lactate dehydrogenase A (46), suggesting that CSP/CSP7–mediated inhibition of HK and lactate causally linked to suppression of HIF-1α. Furthermore, increased glycolysis observed in stromal fibroblasts that nourish surrounding tumor cells show reduced CAV1 expression like fLfs (59). Our results show that CSP/CSP7 restores basal expression of p53 (22) and miR-34a (data not shown), thereby regulating augmented glycolysis. Since p53 is known to transactivate miR-34a and the latter is involved in glucose metabolism (16), we speculated that p53 might directly interact with miR-34a to regulate the expression of glycolytic enzymes in lung fibroblasts. As expected, we found that glycolytic markers were regulated by p53 and miR-34a. In addition, both CSP and CSP7 inhibits AKT/PKB phosphorylation by dephosphorylation and activation of p53 transcriptional target and tumor suppressor protein PTEN (22), leading to reduced metabolic activation. Although proved in vitro, the effects of CSP/CSP7 on glycolysis in animal models still need further exploration. None of the mouse models fully recapitulate all the cardinal manifestations of human IPF. CSP/CSP7 may mitigate pulmonary fibrosis via acting on multiple cell types and attenuation of both inflammatory and fibrotic pathways in vivo (25, 60). Mitigation of lung fibrosis by CSP/CSP7 will alleviate tissue hypoxia, which could also inhibit HIF-1α and glycolysis in vivo.

In summary, we have demonstrated that p53 and its transcriptional target miR-34a regulate glycolysis in lung fibroblasts, and CSP7, when used as a therapeutic agent, ramps down the elevated key enzymes involved in glycolytic pathways in multiple preclinical mouse models of established pulmonary fibrosis and in isolated hLfs and mLfs via restoration of p53 and miR-34a expression. These observations suggest that CSP7 may be a candidate for further development as a therapeutic agent to restrain runaway glycolysis of fLfs required for the initiation and sustainability of the profibrogenic phenotype of these cells that contributes to progressive lung fibrosis.

Methods

Cell isolation and culture. Human nLfs and fLfs (IPF) were purchased from Cory Hogaboam (University of Michigan, Ann Arbor, Michigan, USA), provided by Ganesh Raghu (University of Washington, Seattle, Washington, USA), or isolated locally from control and IPF lung tissues as described elsewhere (22, 25, 61). All hLfs used in the study were well characterized, derived from patients with usual interstitial pneumonia, as described (22, 61). To avoid heterogeneity associated with fLfs, we selected fLfs expressing elevated levels of profibrogenic marker proteins such as collagen-1α, α-SMA, fibronectin, and tenasin-C with minimal expression of CAV1, p53, and PAI-1 as we described earlier (22, 61). Human nLfs were derived from control donors without apparent interstitial or other lung diseases. Mouse nLfs were isolated from the lungs of mice without any lung injury and fLfs from the fibrotic lungs of mice 21 days after exposure to BLM. Primary lung fibroblasts were isolated as described (25, 61). Briefly, human or mouse lung tissues were minced and digested with 0.1% collagenase and 0.005% trypsin in HBSS for 1 hour at 37°C. Fibroblasts were selected by adherence of the suspension on cell culture dishes. The adherent lung fibroblasts were tested for profibrogenic phenotype by analyzing collagen 1α, α-SMA, fibronectin, and tenasin-C, as well as CAV1 and p53 expression; cultured in DMEM containing 4.5 g/L glucose, 10% FBS, and 1% penicillin and streptomycin at 37°C; and used within 3–5 passages of initial isolation.

Lactate and succinate production measurement. Lactate and succinate levels were measured using lactate (catalog K627) colorimetric assay kit II and succinate colorimetric assay kit (catalog K649), respectively (BioVision) according to the manufacturer’s instructions.

Western blotting of cell lysates and lung homogenates. Western blotting was performed as previously described (22, 43, 62). Rabbit anti-HK2 (catalog C64G5), -PKM (catalog D78A4), -PFKP (catalog D4B2), –HIF-1α (catalog D2U3T), and -PFKFB3 (catalog D7H4Q) antibodies were purchased from Cell Signaling Technology. Mouse anti-p53 (catalog SC55476) antibody was purchased from Santa Cruz Biotechnology Inc.

Isolation and analysis of RNA by qPCR. Total RNA, isolated from cells or whole lung homogenates treated with or without CSP, CSP7, or CP, as described above, was reverse transcribed and subjected to qPCR for HK2, PKM, PFKP, PFKFB3, and HIF1A transcripts (22). Primer sequences used in this study have been listed in Table 1.
H&E staining and IHC analyses of lung sections. These analyses were performed as we previously reported (22, 43).

Overexpression and inhibition of p53 or miR-34a in fibroblasts in vitro. hfLfs or mfLfs were transduced with Ad-p53 or Lv–Pre–miR-34a. Naive fLfs and fLfs transduced with Ad-Ev or Lv-Ev were used as controls. In a separate experiment, nLfs in culture dishes were treated with Lv-p53 shRNA or Lv–miR-34a–As to suppress their baseline expression. Naive nLfs and nLfs exposed to nonspecific Ctrl shRNA were used as controls.

Mice. Male and female C57BL/6 mice (8–10 weeks old) were purchased from The Jackson Laboratory. For generation of inducible p53KO or miR34aKO mice lacking expression in fibroblasts, p53fl/fl or miR34afl/fl mice were cross-bred with ColCre mice. First-generation heterozygous fl and ColCre mice were backcrossed with homozygous fl/fl mice. The pups carrying only mutant p53 or miR34a alleles were consecutively given i.p. injection of tamoxifen (75 mg/kg body weight) once every 24 hours for 5 consecutive days to inhibit p53 or miR-34a expression in fibroblasts as described (22). The p53fl/fl or miR34aβ/β and p53KO or miR34aKO mice were exposed to BLM to induce pulmonary fibrosis.

Single-dose BLM-induced pulmonary fibrosis model. WT, p53fl/fl, p53cKO, miR34afl/fl, and miR34a cKO mice were exposed once to freshly prepared BLM (8 U/kg) (catalog RB 003, TSZCHEM) in 50 μL saline or only saline through intranasal instillation. Two weeks after BLM exposure, mice were treated with peptides (1.5 mg/kg/d) for 7 days as we described earlier (22, 25).

TGF-β1–induced pulmonary fibrosis model. WT mice were exposed to saline or 1 × 109 plaque forming units (pfu) of Ad-Ev or Ad–TGF-β1. Two weeks later, mice were treated daily with peptide for 14 days as we described (25, 63).

Multiple-dose BLM-induced pulmonary fibrosis model. WT mice were exposed to BLM (2 U/kg) in 50 μL saline or only saline through intranasal instillation once every 2 weeks, 8 times. Two weeks after the eighth dose, BLM mice were treated with CSP/CSP7 once daily for 2 weeks, as we described (25).

Statistics. The differences between 2 groups were analyzed by 2-tailed Student’s t test and between multiple groups using 1-way ANOVA followed by Tukey’s post hoc test. P < 0.05 was considered statistically significant.

Study approval. All animal experiments reported here were approved by the UTHCT IACUC. The human protocol was approved by the UTHCT IRB.

Author contributions
VG, LF, RSS, and MRN performed the experiments. SS conceived idea and designed the experiments. VG and SS wrote the manuscript.

Acknowledgments
Supported in part by NIH grants R01HL133067-01 and R21ES025815, Flight Attendant Medical Research Institute Clinical Innovator Awards CIA150063 and CIA082380.

Address correspondence to: Sreerama Shetty, Texas Lung Injury Institute, Department of Medicine, University of Texas Health Science Center at Tyler, 11937 US Highway 271, Tyler, Texas 75708, USA. Phone: 903.877.7668; Email: sreerama.shetty@uthct.edu.

1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11–20.
2. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(9):3685–3692.
3. Vander Heiden MG, et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol. 2011;76:325–334.
4. Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem. 2003;278(17):15333–15340.
5. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.
6. Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325–337.
7. Romero-Garcia S, Lopez-Gonzalez JS, B’ez-Viveros JL, Aguilar-Cazares D, Prado-Garcia H. Tumor cell metabolism: an integrative view. Cancer Biol Ther. 2011;12(11):939–948.
8. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.
9. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev
47. Galbán S et al. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.

46. Hu C-J, Wang L-Y, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and...

45. Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic...

44. Kottmann RM et al. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via...

43. Shetty SK et al. p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis.

42. Bhandary YP et al. Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator...

41. Bhandary YP, et al. Role of p53-fibrinolytic system cross-talk in the regulation of quartz-induced lung injury.

40. Ogawara Y et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53.

39. Xia H et al. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis.

38. Zeng Z et al. Activation and overexpression of Sirt1 attenuates lung fibrosis via P300. Biochem Biophys Res Commun.

36. Bucci M et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation.

35. Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.

34. Rangarajan S, et al. Metformin reverses established lung fibrosis in a bleomycin model.

32. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth.

31. Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways.

30. Cui H et al. miR-34a Inhibits Lung Fibrosis by Inducing Lung Fibroblast Senescence.

28. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis.

27. Tarasov V et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target

26. Formenti F et al. Regulation of human metabolism by hypoxia-inducible factor.

25. Marudamuthu AS et al. Caveolin-1-derived peptide limits development of pulmonary fibrosis.

24. Wang XM et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis.

21. Cho SJ, Moon J-S, Lee C-M, Choi AMK, Stout-Delgado HW. Glucose Transporter 1-Dependent Glycolysis Is Increased during...

20. Young CD et al. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One. 2011;6(8):e23205.

19. Zhang C et al. Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD. Oncotarget.

18. Zhang C, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun. 2013;4:2935.

17. Freemerman AJ et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem. 2014;289(11):7884–7896.

16. Kim H-R, Roe J-S, Lee J-E, Cho E-J, Youn H-D. p53 regulates glucose metabolism by miR-34a. Biochem Biophys Res Commun.

15. Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic...

14. Hu C-J, Wang L-Y, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.

13. Formenti F et al. Regulation of human metabolism by hypoxia-inducible factor.

12. Zou H, Stoppani E, Volonte D, Galbiati F. Caveolin-1, cellular senescence and age-related diseases. Mech Ageing Dev. 2011;132(11–12):533–542.

11. Guido C et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with “Warburg-like” cancer metabolism and L-lactate production. Cell Cycle. 2012;11(16):3019–3035.

10. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell.

9. Galbán S et al. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol Cell Biol. 2003;23(20):7083–7095.
48. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci. 2008;65(24):3981–3999.
49. Tzouvelekis A et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1 alpha in disease pathogenesis. Am J Respir Crit Care Med. 2007;176(11):1108–1119.
50. Higgins DF, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007;117(12):3810–3820.
51. Moon J-O, Welch TP, Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G582–592.
52. Hubert A et al. Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level. J Cell Sci. 2006;119(Pt 16):3351–3362.
53. Zhang L, Hill RP. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res. 2004;64(12):4180–4189.
54. Nardinocchi L, Puca R, D’Orazi G. HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation. Aging (Albany NY). 2011;3(1):33–43.
55. Nardinocchi L et al. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One. 2009;4(8):e6819.
56. Laemmle A, et al. Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1α protein under hypoxic conditions. PLoS One. 2012;7(3):e33433.
57. Li H, Rokavec M, Jiang L, Horst D, Hermeking H. Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells. Gastroenterology. 2017;153(2):505–520.
58. Kim J, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27(21):7381–7393.
59. Bhandary YP, et al. Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system. Am J Physiol Lung Cell Mol Physiol. 2012;302(5):L463–L473.
60. Marudamuthu AS, et al. Role of the urokinase-fibrinolytic system in epithelial-mesenchymal transition during lung injury. Am J Pathol. 2015;185(1):55–68.